AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2012
Jun 7, 2012
35334_dirs_2012-06-07_3fb8412c-4e7a-4220-92bb-7666f4d638c4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2012-06-05
Reporting Person: KIANI IRAJ EGHBAL (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-06-05 | Options to buy Common Stock | $0.29 | J | 100000 | Acquired | 2022-06-05 | Common Stock (100000) | Direct |
Footnotes
F1: Board of Directors granted options to purchase shares of HEB common stock.
More from AIM ImmunoTech Inc.
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 14